Skip to main content
. Author manuscript; available in PMC: 2023 Dec 15.
Published in final edited form as: Cancer. 2022 Oct 27;128(24):4241–4250. doi: 10.1002/cncr.34482

Table 2.

National Comprehensive Cancer Network (NCCN) guideline-based cancer surveillance completed as a direct result of cascade genetic testing (N = 25 relatives with pathogenic variants)

Recommendation for cancer screening N %
 Relatives not recommended cancer screening 7
 Relatives recommended cancer screening 18
  Completed ≥1 screening 13 72.2
  Completed all recommended screening 6 33.3
  Completed none of the recommended screening 5 27.8
Screening interventions # Relatives recommended # Relatives completed %
 Mammogram 10 7 70.0
 Breast magnetic resonance imaging (MRI) 10 3 30.0
 Prostate specific antigen screening 1 1 100.0
 Colonoscopy 5 4 80.0
*

Measured NCCN-based cancer screening interventions by mutation: BRCA1 – mammogram, breast MRI; BRCA2 – mammogram, breast MRI, prostate specific antigen for males; CHEK2 – mammogram, breast MRI, colonoscopy; APC I1307K variant – colonoscopy.